Tafamidis delays neurological progression comparably across Val30Met and non ‐Val30Met genotypes in transthyretin familial amyloid polyneuropathy

ConclusionsThis baseline‐adjusted analysis demonstrated that tafamidis treatment delayed neurological progression comparably in Val30Met and non‐Val30Met patients across a range of baseline NIS‐LL values. Neurological progression in these two genotype groups may be more similar than previously considered.

Source: European Journal of Neurology - December 26, 2017 Category: Neurology Authors: B. K. Gundapaneni, M. B. Sultan, D. J. Keohane, J. H. Schwartz Tags: Original Article Source Type: research